Synonyms: I-A/I-E, H-2 class II Clone No.:M5/114
Anti-mouse MHC Class II (I-A/I-E)-InVivo reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. The antibody does not react with I-Af, I-Ak, or I-As haplotypes. The M5/114 antibody is reported to inhibit I-A-restricted T cell responses.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Clone | M5/114 |
|---|---|
| Isotype | Rat IgG2b |
| Application | Anti-mouse MHC Class II (I-A/I-E)-InVivo |
| Source | CHO |
| Purification | Protein G |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.0. Contains no stabilizers or preservatives |
| Murine Pathogen Screening Panel | all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus. |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT07072585 | NOT_YET_RECRUITING | Drug: Bortezomib|Drug: Calaspargase Pegol|Drug: Cyclophospha | Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma | Children's Oncology Group | 2026-08-28 | PHASE2; PHASE3 |
| NCT05463133 | RECRUITING | Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Alemtuzumab|Dru | Chronic Granulomatous Disease | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-08 | PHASE1; PHASE2 |
| NCT07697456 | RECRUITING | Drug: Risankizumab|Drug: Trosunilimab|Drug: ABBV-701 | Crohn's Disease; Ulcerative Colitis | AbbVie | 2026-07-31 | PHASE2 |
| NCT07570966 | WITHDRAWN | Drug: ERW316|Drug: Fulvestrant|Drug: Letrozole | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC) | Novartis Pharmaceuticals | 2026-06-30 | PHASE1; PHASE2 |
| NCT07288359 | RECRUITING | Drug: GVV858|Drug: Fulvestrant|Drug: Letrozole | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer | Novartis Pharmaceuticals | 2025-12-29 | PHASE1; PHASE2 |
| NCT02813135 | RECRUITING | Drug: Ribociclib|Drug: Topotecan|Drug: Temozolomide|Drug: Ev | Pediatric Cancer | Gustave Roussy, Cancer Campus, Grand Paris | 2016-08-03 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-07-30)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.